Hematological Cancers Market Report

Global and Region Hematological Cancers Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：174
  • REPORT CODE：GMM986752
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Hematological Cancers market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Hematological Cancersmarket, defines the market attractiveness level of Hematological Cancers market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Hematological Cancers industry, describes the types of Hematological Cancers market, the applications of major players and the market size, and deeply analyzes the current situation of the global Hematological Cancers market and the development prospects and opportunities of Hematological Cancers industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Hematological Cancers market in Chapter 13.

    By Player:

    • Pharmacyclics

    • Karyopharm Therapeutics

    • Sysmex

    • C R Bard

    • DiagnoCure Inc

    • Siemens AG

    • Johnson & Johnson

    • Mindray Medical International Limited

    • AbbVie

    • Bio-Rad Laboratories

    • The Medicine Company

    • HemoCue AB

    • Kite Pharma

    • Beckman Coulter

    • Curis

    • Astellas Pharma US

    • Celgene Corporation

    • Roche Diagnostics A/S

    • Abbott Laboratories

    • Novartis

    • Horiba

    By Type:

    • Chemotherapy Treatment

    • Targeted Therapy

    • Immunity Therapy

    By End-User:

    • Leukemia

    • Lymphoma

    • Myeloma

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Hematological Cancers Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Hematological Cancers Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Hematological Cancers Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Hematological Cancers Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Hematological Cancers Market Analysis and Outlook to 2022

    • 7.1 Global Hematological Cancers Consumption (2017-2022)

    • 7.2 United States Hematological Cancers Consumption (2017-2022)

    • 7.3 Europe Hematological Cancers Consumption (2017-2022)

    • 7.4 China Hematological Cancers Consumption (2017-2022)

    • 7.5 Japan Hematological Cancers Consumption (2017-2022)

    • 7.6 India Hematological Cancers Consumption (2017-2022)

    • 7.7 South Korea Hematological Cancers Consumption (2017-2022)

    8 Region and Country-wise Hematological Cancers Market Analysis and Outlook to 2028

    • 8.1 Global Hematological Cancers Consumption Forecast (2022-2028)

    • 8.2 United States Hematological Cancers Consumption Forecast (2022-2028)

    • 8.3 Europe Hematological Cancers Consumption Forecast (2022-2028)

    • 8.4 China Hematological Cancers Consumption Forecast (2022-2028)

    • 8.5 Japan Hematological Cancers Consumption Forecast (2022-2028)

    • 8.6 India Hematological Cancers Consumption Forecast (2022-2028)

    • 8.7 South Korea Hematological Cancers Consumption Forecast (2022-2028)

    9 Global Hematological Cancers Market Outlook by Types and Applications to 2022

    • 9.1 Global Hematological Cancers Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Chemotherapy Treatment Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Targeted Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Immunity Therapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Hematological Cancers Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Leukemia Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Lymphoma Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Myeloma Consumption and Growth Rate (2017-2022)

    10 Global Hematological Cancers Market Outlook by Types and Applications to 2028

    • 10.1 Global Hematological Cancers Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Chemotherapy Treatment Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Immunity Therapy Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Hematological Cancers Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Leukemia Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Myeloma Consumption Forecast and Growth Rate (2022-2028)

    11 Global Hematological Cancers Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Hematological Cancers Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Hematological Cancers Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Hematological Cancers Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Hematological Cancers Market Competitive Analysis

    • 14.1 Pharmacyclics

      • 14.1.1 Pharmacyclics Company Details

      • 14.1.2 Pharmacyclics Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Pharmacyclics Hematological Cancers Product and Service

    • 14.2 Karyopharm Therapeutics

      • 14.2.1 Karyopharm Therapeutics Company Details

      • 14.2.2 Karyopharm Therapeutics Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Karyopharm Therapeutics Hematological Cancers Product and Service

    • 14.3 Sysmex

      • 14.3.1 Sysmex Company Details

      • 14.3.2 Sysmex Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Sysmex Hematological Cancers Product and Service

    • 14.4 C R Bard

      • 14.4.1 C R Bard Company Details

      • 14.4.2 C R Bard Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 C R Bard Hematological Cancers Product and Service

    • 14.5 DiagnoCure Inc

      • 14.5.1 DiagnoCure Inc Company Details

      • 14.5.2 DiagnoCure Inc Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 DiagnoCure Inc Hematological Cancers Product and Service

    • 14.6 Siemens AG

      • 14.6.1 Siemens AG Company Details

      • 14.6.2 Siemens AG Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Siemens AG Hematological Cancers Product and Service

    • 14.7 Johnson & Johnson

      • 14.7.1 Johnson & Johnson Company Details

      • 14.7.2 Johnson & Johnson Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Johnson & Johnson Hematological Cancers Product and Service

    • 14.8 Mindray Medical International Limited

      • 14.8.1 Mindray Medical International Limited Company Details

      • 14.8.2 Mindray Medical International Limited Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Mindray Medical International Limited Hematological Cancers Product and Service

    • 14.9 AbbVie

      • 14.9.1 AbbVie Company Details

      • 14.9.2 AbbVie Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 AbbVie Hematological Cancers Product and Service

    • 14.10 Bio-Rad Laboratories

      • 14.10.1 Bio-Rad Laboratories Company Details

      • 14.10.2 Bio-Rad Laboratories Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Bio-Rad Laboratories Hematological Cancers Product and Service

    • 14.11 The Medicine Company

      • 14.11.1 The Medicine Company Company Details

      • 14.11.2 The Medicine Company Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 The Medicine Company Hematological Cancers Product and Service

    • 14.12 HemoCue AB

      • 14.12.1 HemoCue AB Company Details

      • 14.12.2 HemoCue AB Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 HemoCue AB Hematological Cancers Product and Service

    • 14.13 Kite Pharma

      • 14.13.1 Kite Pharma Company Details

      • 14.13.2 Kite Pharma Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Kite Pharma Hematological Cancers Product and Service

    • 14.14 Beckman Coulter

      • 14.14.1 Beckman Coulter Company Details

      • 14.14.2 Beckman Coulter Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Beckman Coulter Hematological Cancers Product and Service

    • 14.15 Curis

      • 14.15.1 Curis Company Details

      • 14.15.2 Curis Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Curis Hematological Cancers Product and Service

    • 14.16 Astellas Pharma US

      • 14.16.1 Astellas Pharma US Company Details

      • 14.16.2 Astellas Pharma US Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Astellas Pharma US Hematological Cancers Product and Service

    • 14.17 Celgene Corporation

      • 14.17.1 Celgene Corporation Company Details

      • 14.17.2 Celgene Corporation Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Celgene Corporation Hematological Cancers Product and Service

    • 14.18 Roche Diagnostics A/S

      • 14.18.1 Roche Diagnostics A/S Company Details

      • 14.18.2 Roche Diagnostics A/S Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Roche Diagnostics A/S Hematological Cancers Product and Service

    • 14.19 Abbott Laboratories

      • 14.19.1 Abbott Laboratories Company Details

      • 14.19.2 Abbott Laboratories Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Abbott Laboratories Hematological Cancers Product and Service

    • 14.20 Novartis

      • 14.20.1 Novartis Company Details

      • 14.20.2 Novartis Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Novartis Hematological Cancers Product and Service

    • 14.21 Horiba

      • 14.21.1 Horiba Company Details

      • 14.21.2 Horiba Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Horiba Hematological Cancers Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Hematological Cancers

    • Figure Hematological Cancers Picture

    • Table Global Hematological Cancers Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Hematological Cancers Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Hematological Cancers Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Hematological Cancers Consumption by Country (2017-2022)

    • Figure United States Hematological Cancers Consumption and Growth Rate (2017-2022)

    • Table Europe Hematological Cancers Consumption and Growth Rate (2017-2022)

    • Figure China Hematological Cancers Consumption and Growth Rate (2017-2022)

    • Figure Japan Hematological Cancers Consumption and Growth Rate (2017-2022)

    • Figure India Hematological Cancers Consumption and Growth Rate (2017-2022)

    • Figure South Korea Hematological Cancers Consumption and Growth Rate (2017-2022)

    • Figure Global Hematological Cancers Consumption Forecast by Country (2022-2028)

    • Figure United States Hematological Cancers Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Hematological Cancers Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Hematological Cancers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Hematological Cancers Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Hematological Cancers Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Hematological Cancers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Immunity Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Leukemia Consumption and Growth Rate (2017-2022)

    • Figure Global Lymphoma Consumption and Growth Rate (2017-2022)

    • Figure Global Myeloma Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunity Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Leukemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Myeloma Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Hematological Cancers Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Hematological Cancers Export by Region (Top 5 Countries) (2017-2028)

    • Table Pharmacyclics (Foundation Year, Company Profile and etc.)

    • Table Pharmacyclics Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pharmacyclics Hematological Cancers Product and Service

    • Table Karyopharm Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Karyopharm Therapeutics Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Karyopharm Therapeutics Hematological Cancers Product and Service

    • Table Sysmex (Foundation Year, Company Profile and etc.)

    • Table Sysmex Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sysmex Hematological Cancers Product and Service

    • Table C R Bard (Foundation Year, Company Profile and etc.)

    • Table C R Bard Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table C R Bard Hematological Cancers Product and Service

    • Table DiagnoCure Inc (Foundation Year, Company Profile and etc.)

    • Table DiagnoCure Inc Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table DiagnoCure Inc Hematological Cancers Product and Service

    • Table Siemens AG (Foundation Year, Company Profile and etc.)

    • Table Siemens AG Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Siemens AG Hematological Cancers Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Hematological Cancers Product and Service

    • Table Mindray Medical International Limited (Foundation Year, Company Profile and etc.)

    • Table Mindray Medical International Limited Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mindray Medical International Limited Hematological Cancers Product and Service

    • Table AbbVie (Foundation Year, Company Profile and etc.)

    • Table AbbVie Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Hematological Cancers Product and Service

    • Table Bio-Rad Laboratories (Foundation Year, Company Profile and etc.)

    • Table Bio-Rad Laboratories Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bio-Rad Laboratories Hematological Cancers Product and Service

    • Table The Medicine Company (Foundation Year, Company Profile and etc.)

    • Table The Medicine Company Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table The Medicine Company Hematological Cancers Product and Service

    • Table HemoCue AB (Foundation Year, Company Profile and etc.)

    • Table HemoCue AB Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table HemoCue AB Hematological Cancers Product and Service

    • Table Kite Pharma (Foundation Year, Company Profile and etc.)

    • Table Kite Pharma Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kite Pharma Hematological Cancers Product and Service

    • Table Beckman Coulter (Foundation Year, Company Profile and etc.)

    • Table Beckman Coulter Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Beckman Coulter Hematological Cancers Product and Service

    • Table Curis (Foundation Year, Company Profile and etc.)

    • Table Curis Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Curis Hematological Cancers Product and Service

    • Table Astellas Pharma US (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma US Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma US Hematological Cancers Product and Service

    • Table Celgene Corporation (Foundation Year, Company Profile and etc.)

    • Table Celgene Corporation Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corporation Hematological Cancers Product and Service

    • Table Roche Diagnostics A/S (Foundation Year, Company Profile and etc.)

    • Table Roche Diagnostics A/S Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Diagnostics A/S Hematological Cancers Product and Service

    • Table Abbott Laboratories (Foundation Year, Company Profile and etc.)

    • Table Abbott Laboratories Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Laboratories Hematological Cancers Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Hematological Cancers Product and Service

    • Table Horiba (Foundation Year, Company Profile and etc.)

    • Table Horiba Hematological Cancers Sales, Price, Value and Gross Profit (2017-2022)

    • Table Horiba Hematological Cancers Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US